Age-Related Tau Burden and Cognitive Deficits Are Attenuated in KLOTHO KL-VS Heterozygotes.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2021
Historique:
pubmed: 12 1 2021
medline: 18 9 2021
entrez: 11 1 2021
Statut: ppublish

Résumé

Identification of new genetic variants that modify Alzheimer's disease (AD) risk will elucidate novel targets for curbing the disease progression or delaying symptom onset. To examine whether the functionally advantageous KLOTHO gene KL-VS variant attenuates age-related alteration in cerebrospinal fluid (CSF) biomarkers or cognitive function in middle-aged and older adults enriched for AD risk. Sample included non-demented adults (N = 225, mean age = 63±8, 68% women) from the Wisconsin Registry for Alzheimer's Prevention and the Wisconsin Alzheimer's Disease Research Center who were genotyped for KL-VS, underwent CSF sampling and had neuropsychological testing data available proximal to CSF draw. Covariate-adjusted multivariate regression examined relationships between age group (Younger versus Older; mean split at 63 years), AD biomarkers, and neuropsychological performance tapping memory and executive function, and whether these relationships differed between KL-VS non-carriers (KL-VSNC) and heterozygote (KL-VSHET). In the pooled analyses, older age was associated with higher levels of total tau (tTau), phosphorylated tau (pTau), and their respective ratios to amyloid-β (Aβ)42 (ps ≤ 0.002), and with poorer performance on neuropsychological tests (ps ≤ 0.001). In the stratified analyses, KL-VSNC exhibited this age-related pattern of associations with CSF biomarkers (all ps ≤ 0.001), and memory and executive function (ps ≤ 0.003), which were attenuated in KL-VSHET (ps ≥ 0.14). Worse memory and executive function, and higher tau burden with age were attenuated in carriers of a functionally advantageous KLOTHO variant. KL-VS heterozygosity seems to be protective against age-related cognitive and biomolecular alterations that confer risk for AD.

Sections du résumé

BACKGROUND
Identification of new genetic variants that modify Alzheimer's disease (AD) risk will elucidate novel targets for curbing the disease progression or delaying symptom onset.
OBJECTIVE
To examine whether the functionally advantageous KLOTHO gene KL-VS variant attenuates age-related alteration in cerebrospinal fluid (CSF) biomarkers or cognitive function in middle-aged and older adults enriched for AD risk.
METHODS
Sample included non-demented adults (N = 225, mean age = 63±8, 68% women) from the Wisconsin Registry for Alzheimer's Prevention and the Wisconsin Alzheimer's Disease Research Center who were genotyped for KL-VS, underwent CSF sampling and had neuropsychological testing data available proximal to CSF draw. Covariate-adjusted multivariate regression examined relationships between age group (Younger versus Older; mean split at 63 years), AD biomarkers, and neuropsychological performance tapping memory and executive function, and whether these relationships differed between KL-VS non-carriers (KL-VSNC) and heterozygote (KL-VSHET).
RESULTS
In the pooled analyses, older age was associated with higher levels of total tau (tTau), phosphorylated tau (pTau), and their respective ratios to amyloid-β (Aβ)42 (ps ≤ 0.002), and with poorer performance on neuropsychological tests (ps ≤ 0.001). In the stratified analyses, KL-VSNC exhibited this age-related pattern of associations with CSF biomarkers (all ps ≤ 0.001), and memory and executive function (ps ≤ 0.003), which were attenuated in KL-VSHET (ps ≥ 0.14).
CONCLUSION
Worse memory and executive function, and higher tau burden with age were attenuated in carriers of a functionally advantageous KLOTHO variant. KL-VS heterozygosity seems to be protective against age-related cognitive and biomolecular alterations that confer risk for AD.

Identifiants

pubmed: 33427737
pii: JAD200944
doi: 10.3233/JAD-200944
pmc: PMC9472657
mid: NIHMS1833078
doi:

Substances chimiques

tau Proteins 0
Glucuronidase EC 3.2.1.31
Klotho Proteins EC 3.2.1.31

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1297-1305

Subventions

Organisme : CSRD VA
ID : I01 CX000555
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG051858
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002373
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062715
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG033514
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS092918
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG027161
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG054047
Pays : United States
Organisme : NIA NIH HHS
ID : K23 AG045957
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR025011
Pays : United States

Commentaires et corrections

Type : ErratumIn

Références

Immun Ageing. 2012 Apr 23;9(1):6
pubmed: 22524317
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Neurobiol Aging. 2019 Apr;76:162-165
pubmed: 30716541
Mech Ageing Dev. 2018 Oct;175:24-34
pubmed: 29890178
Neurology. 2019 Apr 16;92(16):e1878-e1889
pubmed: 30867273
Neurobiol Aging. 2017 Jul;55:91-98
pubmed: 28431289
Neurobiol Aging. 2005 Dec;26 Suppl 1:113-8
pubmed: 16213626
J Gerontol A Biol Sci Med Sci. 2019 Jun 18;74(7):1031-1042
pubmed: 30843026
Aging (Albany NY). 2010 Sep;2(9):567-81
pubmed: 20844315
J Geriatr Psychiatry Neurol. 2005 Dec;18(4):245-9
pubmed: 16306248
Neurology. 2018 Apr 10;90(15):e1306-e1315
pubmed: 29523644
Neurology. 2006 Jun 27;66(12):1837-44
pubmed: 16801647
Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):856-61
pubmed: 11792841
Brain Imaging Behav. 2017 Apr;11(2):391-400
pubmed: 27714549
Ann Neurol. 2006 Dec;60(6):688-95
pubmed: 17192929
Rejuvenation Res. 2014 Apr;17(2):212-6
pubmed: 24164579
Arch Neurol. 2007 Jun;64(6):862-71
pubmed: 17562935
Alzheimers Dement (Amst). 2017 Dec 08;10:130-142
pubmed: 29322089
Ann Clin Transl Neurol. 2015 Mar;2(3):215-30
pubmed: 25815349
J Neurosci. 2015 Feb 11;35(6):2358-71
pubmed: 25673831
Neurobiol Aging. 2019 Nov;83:130-134
pubmed: 31732016
Brain Plast. 2018 Aug 10;3(2):183-194
pubmed: 30151342
JAMA Neurol. 2014 Oct;71(10):1282-9
pubmed: 25155658
Neurobiol Aging. 2019 Nov;83:124-129
pubmed: 31732015
Circ Res. 2005 Mar 4;96(4):412-8
pubmed: 15677572
Alzheimer Dis Assoc Disord. 2009 Apr-Jun;23(2):91-101
pubmed: 19474567
Genet Epidemiol. 2011 Dec;35(8):867-79
pubmed: 22125224
J Alzheimers Dis. 2016 Nov 19;55(2):473-484
pubmed: 27662287
JAMA Neurol. 2020 Jul 1;77(7):849-862
pubmed: 32282020
Nat Rev Neurol. 2019 Oct;15(10):565-581
pubmed: 31501588
Genet Med. 2016 May;18(5):421-30
pubmed: 26312828
Science. 2005 Sep 16;309(5742):1829-33
pubmed: 16123266
Cell Rep. 2014 May 22;7(4):1065-76
pubmed: 24813892
Cell Rep. 2017 Aug 8;20(6):1360-1371
pubmed: 28793260
Neurobiol Aging. 1997 May-Jun;18(3):267-73
pubmed: 9263190
Curr Alzheimer Res. 2011 Jun;8(4):330-5
pubmed: 21222594

Auteurs

Ira Driscoll (I)

Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison, Madison, WI, USA.
Wisconsin Alzheimer's Institute, Madison, WI, USA.
Department of Psychology, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.

Yue Ma (Y)

Wisconsin Alzheimer's Institute, Madison, WI, USA.

Catherine L Gallagher (CL)

Geriatric Research Education and Clinical Center, William S. Middleton VA Hospital, Madison, WI, USA.
Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

Sterling C Johnson (SC)

Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison, Madison, WI, USA.
Wisconsin Alzheimer's Institute, Madison, WI, USA.
Geriatric Research Education and Clinical Center, William S. Middleton VA Hospital, Madison, WI, USA.

Sanjay Asthana (S)

Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison, Madison, WI, USA.
Wisconsin Alzheimer's Institute, Madison, WI, USA.
Geriatric Research Education and Clinical Center, William S. Middleton VA Hospital, Madison, WI, USA.

Bruce P Hermann (BP)

Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison, Madison, WI, USA.
Wisconsin Alzheimer's Institute, Madison, WI, USA.
Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

Mark A Sager (MA)

Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison, Madison, WI, USA.
Wisconsin Alzheimer's Institute, Madison, WI, USA.

Kaj Blennow (K)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Göteborg, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Henrik Zetterberg (H)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Göteborg, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
UK Dementia Research Institute at UCL, London, UK.

Cynthia M Carlsson (CM)

Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison, Madison, WI, USA.
Wisconsin Alzheimer's Institute, Madison, WI, USA.
Geriatric Research Education and Clinical Center, William S. Middleton VA Hospital, Madison, WI, USA.

Corinne D Engelman (CD)

Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison, Madison, WI, USA.
Wisconsin Alzheimer's Institute, Madison, WI, USA.
Departments of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

Dena B Dubal (DB)

Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.

Ozioma C Okonkwo (OC)

Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison, Madison, WI, USA.
Wisconsin Alzheimer's Institute, Madison, WI, USA.
Geriatric Research Education and Clinical Center, William S. Middleton VA Hospital, Madison, WI, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH